Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aytu Bioscience Inc (AYTU)

Aytu Bioscience Inc (AYTU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 165,243
  • Shares Outstanding, K 120,615
  • Annual Sales, $ 7,320 K
  • Annual Income, $ -27,130 K
  • 60-Month Beta -0.12
  • Price/Sales 1.93
  • Price/Cash Flow N/A
  • Price/Book 1.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.01
  • Number of Estimates 1
  • High Estimate 0.01
  • Low Estimate 0.01
  • Prior Year -1.30
  • Growth Rate Est. (year over year) +100.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2800 +7.03%
on 07/09/20
1.7000 -19.41%
on 06/26/20
-0.1100 (-7.43%)
since 06/10/20
3-Month
1.1800 +16.10%
on 04/23/20
2.1300 -35.68%
on 04/27/20
-0.0600 (-4.20%)
since 04/09/20
52-Week
0.3352 +308.71%
on 03/09/20
2.9900 -54.18%
on 03/10/20
-0.4400 (-24.31%)
since 07/10/19

Most Recent Stories

More News
Thinking about buying stock in Unum Therapeutics, Nokia, Amneal Pharmaceuticals, Aytu Bioscience, or Niu Technologies?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for UMRX, NOK, AMRX, AYTU, and NIU.

AYTU : 1.3700 (+2.24%)
NOK : 4.12 (-1.20%)
Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States

Apollo Med Innovations Introduces Novel Research-Based Testing Approach to Offer COVID-19 Antibody Testing to Nationwide Network of Over 1,000 Medical Clinics and Recently Launched Mobile Testing Platform...

AYTU : 1.3700 (+2.24%)
Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

AYTU : 1.3700 (+2.24%)
Thinking about buying stock in Citius Pharmaceuticals, Aytu Bioscience, Applied DNA Sciences, Royal Caribbean Cruises, or American Airlines?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CTXR, AYTU, APDN, RCL, and AAL.

APDN : 8.11 (-0.31%)
AYTU : 1.3700 (+2.24%)
CTXR : 1.3400 (+3.88%)
RCL : 51.77 (+9.87%)
All You Need to Know About Aytu Bioscience, Inc. (AYTU) Rating Upgrade to Strong Buy

Aytu Bioscience, Inc. (AYTU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

AYTU : 1.3700 (+2.24%)
ASLAN Pharmaceuticals (ASLN) Looks Good: Stock Adds 8.7% in Session

ASLAN Pharmaceuticals (ASLN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

AYTU : 1.3700 (+2.24%)
ASLN : 1.8700 (-3.11%)
Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up

Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.

EBS : 94.23 (-0.26%)
AKCA : 13.01 (-2.11%)
MYOV : 18.01 (-3.69%)
AYTU : 1.3700 (+2.24%)
Hand Sanitizers Offer Peace of Mind in an Increasingly Connected World

, /PRNewswire/ -- Under current conditions, many companies in various industries have had to find a niche from which to benefit. In fact, social distancing and disinfecting have become elevated to necessities...

PACM : 10.0000 (+90.48%)
IBIO : 2.22 (-2.63%)
AYTU : 1.3700 (+2.24%)
OPK : 4.02 (unch)
MGPRF : 0.0352 (-37.37%)
MDD.CN : 0.075 (+25.00%)
VXRT : 7.98 (-2.56%)
Is Aytu Bioscience (AYTU) Stock Outpacing Its Medical Peers This Year?

Is (AYTU) Outperforming Other Medical Stocks This Year?

AYTU : 1.3700 (+2.24%)
Alnylam???s Share Price Rises YTD on Pipeline Developments

Alnylam's (ALNY) share price rises more than 14% year to date based on pipeline developments.

ALNY : 162.25 (+2.02%)
AKCA : 13.01 (-2.11%)
AYTU : 1.3700 (+2.24%)
AXLA : 5.09 (-0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade AYTU with:

Business Summary

Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual...

See More

Key Turning Points

2nd Resistance Point 1.4500
1st Resistance Point 1.4100
Last Price 1.3700
1st Support Level 1.3400
2nd Support Level 1.3100

See More

52-Week High 2.9900
Fibonacci 61.8% 1.9759
Fibonacci 50% 1.6626
Last Price 1.3700
Fibonacci 38.2% 1.3493
52-Week Low 0.3352

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar